---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005369"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:34:47.617549+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen reports FY2022 net loss per share $0.38; cash runway into Q1 2024; OCU400 enrollment complete

## Summary
- FY2022 net loss $0.38/share vs $0.30 prior year; Q4 net loss $0.10/share vs $0.07.
- Cash, equivalents, and investments $90.9M as of Dec 31, 2022; estimated runway into Q1 2024.
- OCU400 Phase 1/2 RP enrollment completed; high dose set; Phase 3 targeted end of 2023.
- IND submitted for OCU200 (diabetic macular edema); OCU410/OCU410ST IND planned Q2 2023.
- NeoCart Phase 3 trial design agreed with FDA; start expected H1 2024.

## SEC filing metadata
- accession: 0001628280-23-005369
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/ocgn-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005369
- JSON: https://secwatch.observer/filing/0001628280-23-005369.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005369.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported the year ended December 31, 2022 results: EPS $0.38 net loss per common share.
  - Period: the year ended December 31, 2022
  - EPS: $0.38 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.38 net loss per common share for the year ended December 31, 2022, compared to a $0.30 net loss per common share for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm
- Earnings Releases
  Ocugen, Inc. reported the three months ended December 31, 2022 results: EPS $0.10 net loss per common share.
  - Period: the three months ended December 31, 2022
  - EPS: $0.10 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.10 net loss per common share for the three months ended December 31, 2022, compared to a $0.07 net loss per common share for the three months ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.